These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 17684429)

  • 21. ['Non-inferiority' trials. Tips for the critical reader. Research methodology 3].
    Soonawala D; Dekkers OM
    Ned Tijdschr Geneeskd; 2012; 156(19):A4665. PubMed ID: 22571548
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Missing data handling in non-inferiority and equivalence trials: A systematic review.
    Rabe BA; Day S; Fiero MH; Bell ML
    Pharm Stat; 2018 Sep; 17(5):477-488. PubMed ID: 29797777
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A unifying approach to non-inferiority, equivalence and superiority tests via multiple decision processes.
    Hirotsu C
    Pharm Stat; 2007; 6(3):193-203. PubMed ID: 17879327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Methodological aspects of superiority, equivalence, and non-inferiority trials.
    Stefanos R; Graziella D'; Giovanni T
    Intern Emerg Med; 2020 Sep; 15(6):1085-1091. PubMed ID: 32705494
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship between sample size and the definition of equivalence in non-inferiority drug studies.
    Millar JA; Burke V
    J Clin Pharm Ther; 2002 Oct; 27(5):329-33. PubMed ID: 12383133
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Superiority, equivalence, and non-inferiority trials.
    Lesaffre E
    Bull NYU Hosp Jt Dis; 2008; 66(2):150-4. PubMed ID: 18537788
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Asthma management: the challenge of equivalence.
    Steinijans VW; Neuhäuser M; Hummel T; Leichtl S; Rathgeb F; Keller A
    Int J Clin Pharmacol Ther; 1998 Mar; 36(3):117-25. PubMed ID: 9562226
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The Choice of Priorities in Contemporary Comparative Trials: Superiority vs non Inferiority. Causes and Effects].
    Ageev FT; Yarovaya EB
    Kardiologiia; 2020 Nov; 60(10):107-112. PubMed ID: 33228513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An alternative approach to assess exchangeability of a test treatment and the standard treatment with normally distributed response.
    Tsong Y; Shen M
    J Biopharm Stat; 2007; 17(2):329-38. PubMed ID: 17365227
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multiple testing to establish superiority/equivalence of a new treatment compared with kappa standard treatments.
    Dunnett CW; Tamhane AC
    Stat Med; 1997 Nov; 16(21):2489-506. PubMed ID: 9364656
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trial design for ineffectiveness research: a mixed-methods survey.
    Riggs K; Richman J; Kertesz S
    BMJ Evid Based Med; 2020 Aug; 25(4):143-144. PubMed ID: 31757840
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proving non-inferiority or equivalence of two treatments with dichotomous endpoints using exact methods.
    Chan IS
    Stat Methods Med Res; 2003 Jan; 12(1):37-58. PubMed ID: 12617507
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessing non-inferiority: a combination approach.
    Gao P; Ware JH
    Stat Med; 2008 Feb; 27(3):392-406. PubMed ID: 17575568
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Testing non-inferiority of a new treatment in three-arm clinical trials with binary endpoints.
    Tang NS; Yu B; Tang ML
    BMC Med Res Methodol; 2014 Dec; 14():134. PubMed ID: 25524326
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimal Use of the Non-Inferiority Trial Design.
    Angeli F; Verdecchia P; Vaudo G; Masnaghetti S; Reboldi G
    Pharmaceut Med; 2020 Jun; 34(3):159-165. PubMed ID: 32277352
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Statistical notes. From superiority to non-inferiority clinical trials: a leap in the dark?].
    Marubini E; Rebora P; Reina G
    Ital Heart J Suppl; 2004 Sep; 5(9):712-9. PubMed ID: 15568609
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Similarity/equivalence trials for combination vaccines.
    Blackwelder WC
    Ann N Y Acad Sci; 1995 May; 754():321-8. PubMed ID: 7625668
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of putative placebo in active control trials: two applications in a regulatory setting.
    Durrleman S; Chaikin P
    Stat Med; 2003 Mar; 22(6):941-52. PubMed ID: 12627411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Conducting a cost-effectiveness trial in oncology: justification and method].
    Lejeune C; Binquet C; Bonnetain F
    Bull Cancer; 2009 May; 96(5):603-7. PubMed ID: 19435689
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Trials to assess equivalence: the importance of rigorous methods.
    Jones B; Jarvis P; Lewis JA; Ebbutt AF
    BMJ; 1996 Jul; 313(7048):36-9. PubMed ID: 8664772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.